Core Viewpoint - Silver诺医药-B (02591) announced that on December 1, 2025, the company and its wholly-owned subsidiary, Silver诺技术, will subscribe to a structured deposit product from Ningbo Bank for a total consideration of RMB 125 million, which is equivalent to its total principal amount [1] Group 1 - The total investment amount for the structured deposit product is RMB 125 million [1] - The investment will be made by both Silver诺医药-B and its subsidiary Silver诺技术 [1] - The subscription is set to take place on December 1, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 有關認購結構性存款產品的須予披露交易 董事會宣佈，於2025年12月1日，本公司及銀諾技術（本公司一間直接全資附屬公 司）以代價合共人民幣125,000,000元（即其總本金額）分別向寧波銀行認購一款結 構性存款產品（即寧波銀行結構性存款產品）。 本公司及銀諾技術各自認購寧波銀行結構性存款產品的主要條款載列如下： | 認購方 | 產品名稱 | 本金額 | 認購日期 | 生效日期 | 到期日 | 預期年化回報率 | | --- | --- | --- | --- | --- | --- | --- | | 本公司 | 寧波銀行結構性 | 人民幣 | 2025年12月1日 | 2025年12月3日 | 2025年12月3 ...

Group 1 - Silver诺医药-B (02591.HK) shares increased nearly 7% in a single trading day [2] - Over the past four trading days, the stock price has surged over 50% [2] - As of the latest update, the stock is trading at 44.68 HKD with a transaction volume of 35.366 million HKD [2]

Group 1 - The core viewpoint of the article highlights that Sino Biopharmaceutical-B (02591) has seen a significant stock price increase of over 50% in four trading days, with a current price of 44.68 HKD and a trading volume of 35.37 million HKD [1] - On November 21, the results of the Hang Seng Index series quarterly review were released, and Sino Biopharmaceutical was included in the Hang Seng Composite Index, with the change effective from December 8, 2025 [1] - According to CICC's forecast, Sino Biopharmaceutical is expected to meet the criteria for inclusion in the Hong Kong Stock Connect [1] Group 2 - Sino Biopharmaceutical is focused on the field of metabolic diseases and has a pipeline of innovative drugs targeting conditions such as diabetes, obesity, and non-alcoholic fatty liver disease, all of which are self-developed and possess global intellectual property rights [1] - The company has a comprehensive global research and market layout [1]

Core Viewpoint - Silver诺医药-B (02591) has seen a significant stock price increase, with a rise of over 30% recently, and currently up 6.11% to 40.3 HKD, with a trading volume of 23.13 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B increased by over 30% yesterday [1] - As of the latest update, the stock is trading at 40.3 HKD, reflecting a 6.11% increase [1] - The trading volume reached 23.13 million HKD [1] Group 2: Market Inclusion - On November 21, the results of the Hang Seng Index series quarterly review were announced, with Silver诺医药 being included in the Hang Seng Composite Index [1] - The changes from this review will take effect on December 8, 2025 [1] Group 3: Product and Research Insights - According to a report from Shanghai Securities, Silver诺医药's Supraglutide α demonstrates good safety and efficacy in lowering blood sugar and weight [1] - The company shows significant advantages in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver [1] - The listing on the Hong Kong Stock Exchange is expected to facilitate the advancement of the company's research pipeline and commercialization efforts [1]

每经AI快讯，银诺医药-B(02591.HK)涨超6%，昨日股价飙涨超30%。截至发稿，涨6.11%，报40.3港 元，成交额2313.13万港元。 ...

Core Viewpoint - The expectation for a rate cut by the Federal Reserve in December has increased, leading to a rise in Hong Kong stock indices, with the Hang Seng Index closing up 1.97% at 25,716.5 points, and a total trading volume of 302.64 billion HKD [1] Group 1: Market Performance - The three major indices in Hong Kong collectively rose, with the Hang Seng Index gaining over 2% at one point during the day [1] - The Hang Seng Technology Index increased by 2.78%, closing at 5,545.56 points [1] - The trading volume for the day reached 302.64 billion HKD [1] Group 2: Blue-Chip Stocks - Alibaba-W (09988) saw a significant increase of 4.67%, closing at 154.5 HKD, contributing 104.44 points to the Hang Seng Index [2] - Kuaishou-W (01024) rose by 7.11%, while NetEase-S (09999) increased by 5.87%, contributing 21.51 points and 26.03 points to the index respectively [2] Group 3: Sector Performance - Technology stocks rebounded, with Kuaishou rising over 7% and NetEase nearly 6% [3] - AI applications are gaining traction, with notable increases in stocks related to AI, such as Chuangmeng Tiandi (01119) up 9.38% and Innovation Qizhi (02121) up 8.83% [3] - Military stocks performed strongly, with China Shipbuilding Defense (00317) rising by 13.07% [4] Group 4: Automotive Sector - The automotive sector saw widespread gains, with GAC Group (02238) increasing by 12.03% and Beijing Automotive (01958) rising by 5.91% [5] - The Guangzhou Auto Show featured 93 new car launches, with nearly 60% being new energy vehicles [6] Group 5: Lithium and Semiconductor Stocks - Lithium stocks continued to decline, with Ganfeng Lithium (01772) down 5.66% [7] - Semiconductor stocks showed weakness, with Hua Hong Semiconductor (01347) falling by 4.91% [7] Group 6: Notable Stock Movements - Innovation Industry (02788) debuted with a significant increase of 32.76%, closing at 14.59 HKD [9] - Silver诺医药-B (02591) surged by 31.15% after being included in the Hang Seng Composite Index [10] - Miniso (09896) faced pressure post-earnings, with a decline of 4.84% despite a revenue increase of 28.2% [11]

Core Viewpoint - Silver诺医药-B (02591) has seen a nearly 10% increase in stock price following its inclusion in the Hang Seng Composite Index, effective December 8, 2025, which is expected to enhance its market visibility and support its research and commercialization efforts [1] Group 1: Stock Performance - As of the report, Silver诺医药-B's stock price rose by 9.81%, reaching 31.8 HKD, with a trading volume of 2.7693 million HKD [1] Group 2: Clinical Trials and Product Development - On November 21, it was announced that Silver诺医药 has completed the first patient dosing in a Phase III clinical trial for its core product, Isuparaglutide α, aimed at treating obesity and overweight conditions, with plans to recruit approximately 800 participants [1] - The company has demonstrated that Isuparaglutide α has good safety profiles and significant effects in reducing blood sugar and weight, showing advantages in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver [1] Group 3: Market Outlook and Competition - The GLP-1 sector remains a focus, with ongoing competition intensifying; stakeholders are advised to monitor the expansion of indications, submission for market approval, and the commercialization process [1]

Group 1 - Hong Kong's Hang Seng Index rose by 1.42%, gaining 358 points to close at 25,578 points, while the Hang Seng Tech Index increased by 1.65% [1] - Alibaba-W (09988) surged over 4%, with its Qianwen App surpassing 10 million downloads in its first week of public testing [1] - Sinopharm (01801) rose over 3%, with plans to officially go blue starting December 8 [1] - Hengrui Medicine (01276) increased by over 5%, as nine drugs including SHR-9839 received approval for clinical trials [1] - Beijing Automotive (01958) gained over 3%, planning to sell 51% of its stake in Beiqi International for approximately 1.608 billion yuan to accelerate its international strategy [1] - WeRide (00800) jumped over 6%, having obtained Switzerland's first pure driverless license, with Q3 earnings report upcoming [1] - Rusal (00486) saw an intraday increase of over 4%, announcing plans to cease operations at the Krymni silicon plant by 2026 [1] - GAC Group (02238) surged over 12%, with its all-solid-state battery pilot production line officially completed and put into production [1] - Sino Biopharmaceutical-B (02591) rose over 20%, being included in the Hang Seng Composite Index effective December 8 [1] - 3SBio (01530) increased by over 4%, planning to spin off its subsidiary Mandi International for independent listing [1] Group 2 - Oil stocks continued to decline, with CNOOC (00883) dropping by 2.4% amid easing tensions in the Russia-Ukraine situation [2] - Semiconductor stocks faced significant declines, with Hua Hong Semiconductor (01347) falling over 9% and SMIC (00981) down over 5%, as reports indicated the Trump administration is considering approving exports of Nvidia's H200 AI chips to China [2] - Ganfeng Lithium (01772) dropped over 7%, facing potential downward risks in lithium spot prices, leading Goldman Sachs to downgrade the company to a "sell" rating [2]

Group 1: Market Movements - Sangfor Technologies (01530) rose over 5% following the news that Mandi International has submitted an application to list on the Hong Kong Stock Exchange, focusing on skin health and weight management solutions [1] - Yino Pharma (02591) surged over 22.5% after being included in the Hang Seng Composite Index, effective December 8, 2025 [1] - ASMPT (00522) fell over 2% as it was removed from the Hang Seng Tech Index [1] - Semiconductor stocks faced declines, with Hua Hong Semiconductor (01347) down 9.35% and SMIC (00981) down 5.38%, amid reports of potential U.S. chip exports to China [1] - Ganfeng Lithium (01772) dropped over 7% due to Goldman Sachs' report indicating that while the lithium market fundamentals have improved, extended inventory cycles in energy storage may offset this [1] Group 2: Company Earnings and Performance - Miniso (09896) fell over 6% despite reporting a 28.2% year-on-year revenue increase, as net profit dropped over 30% compared to the previous year [2] - NetEase (09999) rose over 5% after reporting a net income of RMB 28.4 billion (approximately $4 billion), an 8.2% year-on-year increase [2] - Alibaba (09988) increased over 4% as its AI assistant app surpassed 10 million downloads within a week of public testing [2] - CK Hutchison (00001) rose nearly 3% amid reports of plans for a dual listing of its Watsons brand, potentially raising up to $2 billion [2] Group 3: U.S. Market Highlights - Nvidia (NVDA.US) continued its downward trend, falling 0.97% despite a strong earnings report, with the founder expressing frustration over market perceptions [3] - Oracle (ORCL.US) dropped 5.66% after issuing $18 billion in investment-grade bonds to increase AI spending [4] - Retailer Ross Stores (ROST.US) saw an increase of over 8.41% after reporting third-quarter sales of $5.6 billion, exceeding market expectations [5] - Intuit (INTU.US) rose over 4.03% after reporting adjusted earnings per share of $3.34, surpassing Wall Street's expectations [5]